Here are the DEF 14A proxy statements from Syra Health Corp A (SYRA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow SYRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SYRA filings page.
Syra Health Corp. is asking stockholders to vote at its July 23, 2026 annual meeting on three items: electing five directors, ratifying M&K CPAS, PLLC as independent auditor for 2026, and expanding the 2022 Omnibus Equity Incentive Plan to 4,100,000 Class A shares.
As of May 28, 2026, there were 13,839,169 Class A shares and 350,000 Class B shares outstanding, with Class B carrying 16.5 votes per share. The proxy details board independence, committee structures, and director pay, including cash retainers and stock options. It also outlines executive compensation and new CEO Gregory R. Alexander’s employment terms, including a $251,000 base salary and sizable equity awards tied to time-based vesting, performance goals, and potential change-in-control treatment.